Pharmaceuticals: DSM Joint Venture Percivia Ceases Inhouse Activities

DSM and Crucell (Leiden, the Netherlands), a biotech firm, have pulled the plug on all inhouse projects at their biosimilar drugs joint venture company Percivia (Cambridge, MA). Set up in 2007, “Percivia will remain as an entity to serve existing licensees,” DSM tells CW. DSM says that an undisclosed number of staff will be made redundant as a result of the jv’s change of strategy.   Percivia’s business has been based on the use of Crucell’s PER.C6 engineered human cell line that has been specifically developed for industrial...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers